1 / 51

Clostridium botulinum Toxin: The Neuromuscular Wonder Drug

Clostridium botulinum Toxin: The Neuromuscular Wonder Drug. Amy Malhowski Biology 360 March 30, 2005. Figure taken from: http://www.consultingroom.com/Aesthetics/Products/Product_Display.asp?ID=1. Public Perception of Botulinum Toxin. Bioterrorism!.

daniel_millan
Download Presentation

Clostridium botulinum Toxin: The Neuromuscular Wonder Drug

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clostridium botulinum Toxin:The Neuromuscular Wonder Drug Amy Malhowski Biology 360 March 30, 2005 Figure taken from: http://www.consultingroom.com/Aesthetics/Products/Product_Display.asp?ID=1

  2. Public Perception of Botulinum Toxin Bioterrorism! Figures taken from: http://www.safetycentral.com/bottoxfacin.html http://archives.cnn.com/2002/ALLPOLITICS/06/12/bush.terror/

  3. And of course…Botox®Aka “The Fountain of Youth” Figure taken from: http://lingua.utdallas.edu:7000/1442/

  4. Outline of Talk • Historical background of C. botulinum • Transmission of Botulinum toxin • Molecular pathogenesis • Therapeutic uses of Botulinum toxin • Concluding remarks

  5. What is Botulism? • Flaccid paralysis of muscles • by toxin from Clostridium botulinum • Three types – via route of entry of bacteria • Foodborne, infant, wound • Mainly foodborne outbreaks • Now bioterrorism threat

  6. The History of Botulinum Toxin • “botulism” from botulus (sausage) from outbreak of consuming improperly cooked sausage • Published 1st case studies on botulinum intoxication • Accurately described neurological symptoms • 1st to propose therapeutic use of toxin Figure adapted from: Erbguth, 2004.

  7. Symptoms of Botulism Figure taken from Caya, et al., 2004.

  8. Finding the Culprit • Emile Pierre van Ermengem (1895) • 1st to connect botulism to bacterium from raw, salted pork & postmortem tissues of botulism victims • Isolated bacterium, naming it Bacillus botulinus

  9. Clostridium botulinum • Strict anaerobe • Gram-positive • Bacillus (rod) shape • Ubiquitous in terrestrial environment • Virulence factor = Botulinum toxin • Released under specific conditions Figure taken from http://www.jhsph.edu/Publications/Special/cover2.htm

  10. Botulism and Bioterrorism • Great potential in toxicity • Toxin tested as bioweapon during WWII • aborted when toxin did not affect test animals (donkeys) • BoNT no longer considered good bioweapon

  11. Mass Producing Botulinum Toxin • Fort Detrick (1946) – bioweapon research – 1st time mass produce toxin • Nixon terminates all research on biowarfare agents (1972) • Schantz produces batch 79-11 (1979) • used until 1997 • Batches made in 1991 • Botox® by Allergan Inc., Irvine, CA

  12. So what?Importance of C. botulinum Research • Bioterrorism/outbreaks • Kerner – use in therapeutics • Recently – BoNT as therapeutic agent for neuromuscular disorders

  13. Outline of Talk • Historical background of C. botulinum • Transmission of Botulinum toxin • Molecular pathogenesis • Therapeutic uses of Botulinum toxin • Impediments in Treatment • Concluding remarks

  14. Transmission of Botulinum Toxin • Mostly via improperly cooked food • Conditions to produce toxin not completely understood • Complex route of transmission • Ingestion/injection • Progenitor toxin complex • Absorbed into tissue  circulated in blood • Dock onto receptors of neuron  transcytosis  binds up acetylcholine  paralysis

  15. Classes of Botulinum Toxin • Seven different subtypes of botulinum toxin • A, B, C1, D, E, F, and G • Same general mechanism for muscular paralysis • Vary in structure, target site, & toxicity • Only two manufactured for commercial use • A and B

  16. Target Proteins of Botulinum Toxins Figure adapted from: Aoki. 2004. Curr Med Chem. 11: 3085-3092.

  17. Outline of Talk • Historical background of C. botulinum • Transmission of Botulinum toxin • Molecular pathogenesis • Therapeutic uses of Botulinum toxin • Impediments in Treatment • Concluding remarks

  18. Molecular Pathogenesis of BoNT BoNT synthesized as single-chain polypeptide (inactive form) Polypeptide cleaved by protease to create dichain structure (active form) BoNT binds to epithelium, transcytosed, reaches general circulation Receptor-mediated endocytosis at peripheral cholinergic nerve endings In cytosol, toxin cleaves target, blocking neurotransmitter release = flaccid paralysis

  19. Major Steps in BoNT Action Figure taken from: Simpson. 2004. Annu. Rev. Pharmacol. Toxicol. 44: 161-193.

  20. Genetic Organization of Botulinum Locus in Clostridium botulinum v RNAP Core BotR/A 5’ 3’ haoperon ntnh-bont/A operon ha70 ha17 ha34 botR/A ntnh bont/A Figure adapted from: Raffestin, S., et al., 2005. Molec. Microbiol. 55: 235-249.

  21. Botulinum Toxin Type A Aoki. 2004. Curr Med Chem. 11: 3085-3092. Simpson. 2004. Annu. Rev. Pharmacol. Toxicol. 44: 161-193.

  22. Figure taken from: Arnon, et al. 2001.

  23. Uses of Botulinum Toxin • Bioterrorism agent – Category A • Local paralytic agent – Botox® • Therapeutic agent • Neuromuscular disorders • Pain management

  24. BoNT as Local Paralytic Agent • Use Botulinum toxin type A (Botox®) • Many cosmetic uses • Few clinical side effects • Fast acting – 6 hours post injection • Effects last 3-6 months • Serial injections required to maintain results

  25. BoNT/A Induces Local Paralysis • Local effects = dose dependent • Injection site affects physical outcome After Botox® Before Botox® Figures adapted from: Mendez-Eastman. 2003. Plast. Surg. Nurs. 23:64-70.

  26. Outline of Talk • Historical background of C. botulinum • Transmission of Botulinum toxin • Molecular pathogenesis • Therapeutic uses of Botulinum toxin • Impediments in Treatment • Concluding remarks

  27. BoNT as a Therapeutic Agent • Botox® used in aesthetics  therapeutic use in neuromuscular disorders • BoNT/A = Botox® - Allergan, Inc. • BoNT/B = MYOBLOC™ - Elan Pharmaceuticals

  28. BoNT as Therapeutic Agent in Neuromuscular Disorders • Purified BoNT/A = Botox® • Treat medical conditions characterized by muscle hyperactivity/spasm • blepharospasm, strabismus, cervical dystonia, glabellar lines, spastic dystonia, limb spasticity, tremors, chronic anal fissure, hyperhidrosis, etc. • Currently only FDA approved for 4 disorders • Blepharospasm (focal dystonia) • Strabismus • Cervical dystonia • Hyperhidrosis

  29. BoNT/A & Muscle Hyperactivity Cervical Dystonia (CD) • CD – involuntary contractions of neck and shoulder muscles • FDA approved injections with BoNT/A (2000) • BoNT/A injected into affected muscles to reduce muscle contraction • BoNT/A effectively reduces muscle spasticity and pain associated with CD

  30. Cervical Dystonia Study with Botox® by Allergan, Inc. • Phase 3 randomized, multi-center, double blind, placebo-controlled study on treatment of CD with Botox ® (1998) • 170 subjects (88 in Botox® group, 82 in placebo group), analyzed until 10 wks post-injection • Study suggests majority of patients had beneficial response by 6th week

  31. Cervical Dystonia Study with BoNT/A as Dysport® • Multicenter, double-blind, randomized, controlled trial with Dysport® to treat CD in the USA (2005) • Patients (80) randomly assigned to receive Dysport® (500U) or placebo • Dysport® significantly more effective than placebo at weeks 4, 8, and 12 • Dysport® group had 38% with positive treatment response, with median duration of response of 18.5 weeks

  32. BoNT/A & Pain Management • BoNT use in controlling pain-associated disorders • Data suggests BoNT acts in complex manner – not just controlling overactive muscle • BoNT inhibits the release of neurotransmitters (glutamate and substance P) involved in pain transmission

  33. Peripheral and Central Nervous System Sensitization Figure taken from: Aoki, 2003.

  34. Botulinum Toxin A Affects Sensitization of PNS & CNS Figure taken from: Aoki, 2003.

  35. Antinociceptive Activity of BoNT/A • Acute pain (phase 1) - not relieved by BoNT/A • Inflammatory pain (phase II) - relieved by BoNT/A • Increasing doses decrease phase II pain appreciably • Antinociceptive activity maintained longer with higher dose of BoNT/A Figure taken from:Aoki, 2003.

  36. BoNT/A Injection Reduces Formalin-induced Pain • Formalin challenge 5 days post-injection with BoNT  dose-dependent decrease in Glut release • BoNT/A prevents increase of formalin-induced Glut release Figure taken from:Aoki, 2003.

  37. BoNT/A Reduces Pain • Antinociceptive • Activity of BoNT/A in • formalin-challenged rats. B) Subcutaneous BoNT/A injection reduces formalin-induced glutamate release in rat paw in a formalin-challenged inflammatory pain animal model. Figures taken from:Aoki, 2003.

  38. Conclusions on Therapeutics • BoNT mechanism = specific • Uses are diverse • Local flaccid paralysis • Reducing muscle spasticity • Reducing pain • Currently use of BoNT • muscle disorders and associated pain

  39. Outline of Talk • Historical background of C. botulinum • Transmission of Botulinum toxin • Molecular pathogenesis • Therapeutic uses of Botulinum toxin • Impediments in Treatment • Concluding remarks

  40. Impediments in Treating with BoNT • FDA approval pending for many disorders • Fleeting effects – need repeated injections • Socioeconomics – less expensive than surgery BUT not permanent • Social constraints – • More research needed • stigma in using deadly toxin for good use

  41. Concluding Remarks • Toxin = great therapeutic agent! • Research needed to understand mechanism of release of BoNT from C. botulinum • Few impediments in therapeutics • Future with Botox® is bright!

  42. And remember… Sometimes wrinkles aren’t all that bad!

  43. Thank you! • Chris White-Ziegler • My readers: Caitlin Reed & Natalia Grob • Bio 360 students Figure taken from: http://www.jwolfe.clara.net/Humour/MedMiscel.htm

  44. References • Aoki, K.R. 2001. A Comparison of the Safety Margins of Botulinum Neurotoxin Serotypes A, B, and F in Mice. Toxicon. 39: 1815-1820. • Aoki, K.R. 2003. Evidence for Antinociceptive Activity of Botulinum Toxin Type A in Pain Management. Headache. 43: S9-S15. • Aoki, K.R. 2004. Botulinum Toxin: A Successful Therapeutic Protein. Curr. Med. Chem. 11: 3085-3092. • Arnon, et al. 2001. Botulinum Toxin as Biological Weapon. JAMA. 285: 1059- 2081. • Bossi, P., A. Tegnell, A. Baka, F. Van Loock, J. Hendriks, A. Werner, H. Maidhof, and G. Gouvras. 2004. Bichat Guidelines for the Clinical Management of Botulism and Bioterrorism-related Botulism. Eurosurveillance. 9: 1-4. • Breldenbach, M.A. and A.T. Brunger. 2004. Substrate Recognition Strategy for Botulinum Neurotoxin Serotype A. Nature. 432: 925-929. • Casadevall, A., E. Dadachova, and L. Pirofski. 2004. Passive Antibody Therapy for Infectious Diseases. Nat Rev Microbiol. 2: 695-703. • Casadevall, A. and L. Pirofski. 2004. The Weapon Potential of a Microbe. Trends Microbiol. 12: 259-263. • Caya, J.G., R. Agoi, and J.E. Miller. 2004. Clostridium botulinum and the Clinical Laboratorian: A Detailed Review of Botulism, Including Biological Warfare Ramifications of Botulinum Toxin. Arch Pathol Lab Med. 128: 653-662.

  45. References • CDC Botulism Emergency Preparedness & Response. http://www.bt.cdc.gov/agent/botulism/ Accessed 3/25/05. • Chaddock, J.A., J.R. Purkiss, L.M. Friis, J.D. Broadbridge, M.J. Duggan, S.J. Fooks, C.C. Shone, C.P. Quinn, and K.A. Foster. Inhibition of Vesicular Secretion In Both Neuronal and Nonneuronal Cells by a Retargeted Endopeptidase Derivative of Clostridium botulinum Type A. Infect. Immun. 68: 2587-2593. • Coffield, J.A., N.M. Bakry, A.B. Maksymowych, and L.L. Simpson. 1999. Characterization of a Vertebrate Neuromuscular Junction That Demonstrates Selective Resistance to Botulinum Toxin. J. Pharmacol. Exp. Ther. 289: 1509-1516. • Coffield, J.A., N.M. Bakry, R.-d. Zhang, J. Carlson, L.G. Gomella, and L.L. Simpson. 1997. In Vitro Characterization of Botulinum Toxin Types A, C and D Action on Human Tissues: Combined Electrophysiologic, Pharmacologic and Molecular Biologic Approaches. J. Pharmacol. Exp. Ther. 280: 1489-1498. • Cui, M., S. Khanijou, J. Rubino, and K.R. Aoki. 2004. Subcutaneous Administration of Botulinum Toxin A Reduces Formalin-Induced Pain. Pain. 107: 125-133.

  46. References • De Paiva, A., F.A. Meunier, J. Molgo, K.R. Aoki, and J.O. Dolly. 1999. Functional Repair of Motor Endplates After Botulinum Neurotoxin Type A Poisoning: Biphasic Switch of Synaptic Activity Between Nerve Sprouts and their Parent Terminals. Proc. Natl. Acad. Sci. USA. 96: 3200-3205. • Erbguth, F.J. 2004. Historical Notes on Botulism, Clostridium botulinum, Botulinum Toxin, and the Idea of the Therapeutic Use of the Toxin. Mov Dis. 19: S2-S6. • Fernandez-Salas, E., H. Ho, P. Garay, L.E. Steward, and K.R. Aoki. 2004. Is the Light Chain Subcellular Localization an Important Factor in Botulinum Toxin Duration of Action? Mov. Dis. 19: S23-S34. • Fernandez-Salas, E., L.E. Steward, H. Ho, P.E. Garay, S.W. Sun, M.A. Gilmore, J.V. Ordas, J. Wang, J. Francis, and K.R. Aoki. 2004. Plasma Membrane Localization Signals in the Light Chain of Botulinum Neurotoxin. Proc. Natl. Acad. Sci. USA. 101: 3208-3213. • Foran, P.G., N. Mohammed, G.O. Lisk, S. Nagwaney, G.W. Lawrence, E. Johnson, L. Smith, K.R. Aoki, and J.O. Dolly. 2003. Evaluation of the Therapeutic Usefulness of Botulinum Neurotoxin B, C1, E, and F Compared with the Long Lasting Type A: Basis for Distinct Durations of Inhibition of Exocytosis in Central Neurons. J. Biol. Chem. 278: 1363-1371.

  47. References • Franciosa, G., M. Pourshaban, A. De Luca, A. Buccino, B. Dallapiccola, and P. Aureli. 2004. Identification of Type A, B, E, and F Botulinum Neurotoxin Genes and of Botulinum Neurotoxigenic Clostridia by Denaturing High-Performance Liquid Chromatography. App Env Microbiol. 70: 4170-4176. • Hall, Y.H.J., J.A. Chaddock, H.J. Moulsdale, E.R. Kirby, F.C.G. Alexander, J.D. Marks, and K.A. Foster. 2004. Novel Application of an in vitro Technique to the Detection and Quantification of Botulinum Neurotoxin Antibodies. J. Immun. Met. 288: 55-60. • Hong, B., L. Jiang, Y. Hu, D. Fang, and H. Guo. 2004. J. Microbiol. Met. 58: 403- 411. • Jathoul, A.P., J.L. Holley, and H.S. Garmory. 2004. Efficacy of DNA Vaccines Expressing the Type F Botulinum Toxin Hc Fragment Using Different Promoters. Vaccine. 22: 3942-3946. • Johnson, E.A. and M. Bradshaw. 2001. Clostridium botulinum and Its Neurotoxins: A Metabolic and Cellular Perspective. Toxicon. 39: 1703- 1722. • Johnston, M.D., S. Lawson, and J.A. Otter. 2005. Evaluation of Hydrogen Peroxide Vapour as a Method for the Decontamination of Surfaces Contaminated with Clostridium botulinum Spores. J. Microbiol. Met. 60: 403-411.

  48. References • Lacy, D.B., W. Tepp, A.C. Cohen, B.R. DasGupta, and R.C. Stevens. 1998. Crystal Structure of Botulinum Neurotoxin Type A and Implications for Toxicity. Nat. Struct. Biol. 5: 898-902. • Lew, M.F. 2002. Review of the FDA-Approved Uses of Botulinum Toxins, Including Data Suggesting Efficacy in Pain Reduction. Clin. J. Pain. 18: S142-S46. • Lovenklev, J. E. Holst, E. Borch, and P. Radstrom. 2004. Relative Neurotoxin Gene Expression in Clostridium botulinum Type B, Determined Using Quantitative Reverse Transcription-PCR. App Env Microbiol. 70: 2919-2927. • Maksymowych, A.B. and L.L. Simpson. 1998. Binding and Transcytosis of Botulinum Neurotoxin by Polarized Human Colon Carcinoma Cells. J. Biol. Chem. 273: 21950-21957. • Maksymowych, A.B., M. Reinhard, C.J. Malizio, M.C. Goodnough, E.A. Johnson, and L.L. Simpson. 1999. Pure Botulinum Neurotoxin Is Absorbed from the Stomach and Small Intestine and Produces Peripheral Neuromuscular Blockade. Infect. Immun. 67: 4708-4712. • Marvaud, J.C., S. Raffestin, M. Gibert, and M.R. Popoff. 2000. Regulation of the Toxigenesis in Clostridium botulinum and Clostridium tetani. Biol. Cell. 92: 455-457. • McLaughlin, J.B., J. Sobel, T. Lynn, E. Funk, and J.P. Middaugh. 2004. Botulism Type E Outbreak Associated with Eating a Beached Whale, Alaska. Emerg. Infect. Dis. 10: 1685-1687.

  49. References • Mendez-Eastman, S.K. 2003. BOTOX: A Review. Plast Surg Nurs. 23: 64-70. • Merrison, A.F.A., K.E. Chidley, J. Dunnett, and K.A. Sieradzan. 2005. Lesson of the Week: Wound Botulism Associated with Subcutaneous Drug Use. BJM. 325: 1020-1021. • Park, J. and L.L. Simpson. 2003. Inhalational Poisoning by Botulinum Toxin and Inhalation Vaccination with Its Heavy-Chain Component. Infect & Immun. 71: 1147-1154. • Park, J. and L.L. Simpson. 2004. Progress Toward Development of an Inhalation Vaccine Against Botulinum Toxin. Expert Rev. Vacc. 3: 477- 487. • Purkiss, J., M. Welch, S. Doward, and K. Foster. 2000. Capsaicin-Stimulated Release of Substance P from Cultured Dorsal Root Ganglion Neurons: Involvement of Two Distinct Mechanisms. Biochem. Pharm. 59: 1403- 1406. • Raffestin, S. B. Dupuy, J.C. Marvaud, and M.R. Popoff. 2005. BotR/A and TetR are Alternative RNA Polymerase Sigma Factors Controlling the Expression of the Neurotoxin and Associated Protein Genes in Clostridium botulinum Type A and Clostridium tetani.Molec. Microbiol. 55: 235-249. • Rohrich, R.J., J.E. Janis., S. Fagien, and J.M. Stuzin. 2003. The Cosmetic Use of Botulinum Toxin. CME Plast. Reconstr. Surg. 112: S177-S187.

  50. References • Sahai, A, M. Khan, C.J. Fowler, and P. Dasgupta. 2005. Botulinum Toxin for the Treatment of Lower Urinary Tract Symptoms: A Review. Neurourology. 24: 2-12. • Scott, A.B. 2004. Development of Botulinum Toxin Therapy. Dermatol. Clin. 22: 131-133. • Simpson, L.L. 1986. A Preclinical Evaluation of Aminopyridines as Putative Therapeutic Agents in the Treatment of Botulism. Infect. Immun. 52: 858-862. • Simpson, L.L., A.B. Maksymowych, and S. Hao. 2001. The Role of Zinc Binding in the Biological Activity of Botulinum Toxin. J. Biol. Chem. 276: 27034-27041. • Simpson, L.L., H. Zepeda, and I. Ohishi. 1988. Partial Characterization of the Enzymatic Activity Associated with the Binary Toxin (Type C2) Produced by Clostridium botulinum.Infect. Immun. 56: 24-27. • Simpson, L.L., J.A. Coffield, and N. Bakry. 1993. Chelation of Zinc Antagonizes the Neuromuscular Blocking Properties of the Seven Serotypes of Botulinum Neurotoxin as well as Tetanus Toxin. J. Pharmacol. Exp. Ther. 267: 720-727. • Simpson, L.L., Y. Kamata, and S. Kozaki. 1990. Use of Monoclonal Antibodies as Probes for the Structure and Biological Activity of Botulinum Neurotoxin. J. Pharmacol Exp Ther. 255: 227-232.

More Related